[
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamase (ESBL)-producing Klebsiella pneumoniae or other 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE), the recommended targeted therapy depends on",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCeph are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of beta-lactam/beta-lactam",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative and Gram-positive bacteria, including those that cause complex infections in critically ill patients, such as those with CRAB (community-acquired or healthcare-associated bloodstream infections caused by multidrug-",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder (PTLD).\n\nIn the context of surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically a carbapenem antibiotic.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical situation and microbiological data.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing regimens, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10217061573080431,
                    "2_gram": 0.158463625867471,
                    "3_gram": 0.11864389143665985,
                    "4_gram": 0.08957886674240999
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.201215361161611,
                        "recall": 0.45013772564522453,
                        "fmeasure": 0.27093578369374244
                    },
                    "rouge_L": {
                        "precision": 0.1543482208683407,
                        "recall": 0.3553869703884853,
                        "fmeasure": 0.21009151620253844
                    }
                },
                "METEOR": 0.24753417335474495,
                "BERTScore": {
                    "Precision": -0.044,
                    "Recall": 0.197,
                    "F1_measure": 0.075
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.19814184854689607,
                    "2_gram": 0.28417199768148266,
                    "3_gram": 0.24099901199824286,
                    "4_gram": 0.1936297271830114
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3778920241184392,
                        "recall": 0.43313823703158655,
                        "fmeasure": 0.36470572634511894
                    },
                    "rouge_L": {
                        "precision": 0.32147621770263285,
                        "recall": 0.35165928042007427,
                        "fmeasure": 0.306784312165412
                    }
                },
                "METEOR": 0.31562256163271163,
                "BERTScore": {
                    "Precision": 0.251,
                    "Recall": 0.391,
                    "F1_measure": 0.319
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamases (ESBLs) producing 3rd generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), the recommended targeted therapy is a carbapenem antibiotic. Car",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the National Institute for Health",
                "The recommendation for combination therapy in patients with carbapenem-resistant Enterobacterales (CRE) infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol depends on several factors, including the severity of the infection, the patient's clinical condition, and the local epidemiology of CRE.\n\nThe Infectious Diseases Society of America (IDSA) and the European Society of Clin",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad range of Gram-negative and Gram-positive bacteria, including those causing complex intra-abdominal infections (cIAI), including those caused by Carbapenem-resistant Acinetobacter baumannii (CRAB).",
                "ESCR-E (E-cadherin gene mutation causing E-cadherin loss of function, also known as Epithelial-to-Mesenchymal Transition-Ecadherin) carrier status is associated with an increased risk of postoperative infections, including infections after liver transplantation. E-cadherin is a key protein involved in maintaining the integrity of epithelial tissues, and its loss can lead to increased cellular mobility and susceptibility to bacterial invasion. Several studies have",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Study population: Define the study population based on patient characteristics, such as age, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as imipenem or meropenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3GCephalosporin-resistant Enterobacteriaceae (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for patients with severe infections or those at high risk for treatment failure. The specific agents and dosing regimens depend on the susceptibility patterns of the isolate and the patient's clinical condition. Consulting an",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. No definitive conclusions have been made yet.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic regimen: Choice"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10146014881739525,
                    "2_gram": 0.15732299145906722,
                    "3_gram": 0.12424654166950466,
                    "4_gram": 0.0989483081194694
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.22111236769640982,
                        "recall": 0.514861965759557,
                        "fmeasure": 0.30383662524715394
                    },
                    "rouge_L": {
                        "precision": 0.16210708611761238,
                        "recall": 0.38066372419122,
                        "fmeasure": 0.22386491015715532
                    }
                },
                "METEOR": 0.3151098998778948,
                "BERTScore": {
                    "Precision": -0.013,
                    "Recall": 0.327,
                    "F1_measure": 0.152
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18045314221781655,
                    "2_gram": 0.2673041709391336,
                    "3_gram": 0.2334074636165853,
                    "4_gram": 0.18999286284110056
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4056406689947063,
                        "recall": 0.5497819193660732,
                        "fmeasure": 0.40446609407456463
                    },
                    "rouge_L": {
                        "precision": 0.36057276988954007,
                        "recall": 0.49004700265872814,
                        "fmeasure": 0.36104130645125015
                    }
                },
                "METEOR": 0.3517786456300328,
                "BERTScore": {
                    "Precision": 0.31,
                    "Recall": 0.454,
                    "F1_measure": 0.378
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol. The goal of combination therapy is to increase the likelihood of microbiological and clinical success, reduce the risk of developing resistance, and decrease the emergence of superinfections.\n\nThe choice of",
                "Eravacycline is a new, lipid-linked, fluorinated tetracycline antibiotic that has shown activity against multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical efficacy of eravacycline against CRAB infections is still being investigated.\n\nSever",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including demographics, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in the current guidelines. However, the use of combination therapy is suggested for certain patient populations, such as those with severe infections or those at risk for treatment failure. The specific choice of agents for combination therapy depends on the susceptibility profile of the isolate and the patient's clinical condition",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.0967934765741134,
                    "2_gram": 0.15042081213477834,
                    "3_gram": 0.12059148444865674,
                    "4_gram": 0.09277436356388888
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20263646380858122,
                        "recall": 0.44593191347471,
                        "fmeasure": 0.2723359328869596
                    },
                    "rouge_L": {
                        "precision": 0.1635783492431857,
                        "recall": 0.3659786997160122,
                        "fmeasure": 0.22100510338590745
                    }
                },
                "METEOR": 0.27091116648599406,
                "BERTScore": {
                    "Precision": 0.024,
                    "Recall": 0.26,
                    "F1_measure": 0.14
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18237589812703145,
                    "2_gram": 0.2648975984515181,
                    "3_gram": 0.21926233897023434,
                    "4_gram": 0.17381870079040693
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3489510290581461,
                        "recall": 0.4445705877496516,
                        "fmeasure": 0.3407598966997463
                    },
                    "rouge_L": {
                        "precision": 0.30138905349122674,
                        "recall": 0.3992084933419579,
                        "fmeasure": 0.3002818676502887
                    }
                },
                "METEOR": 0.3015359558398559,
                "BERTScore": {
                    "Precision": 0.206,
                    "Recall": 0.382,
                    "F1_measure": 0.291
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. They use rigorous methods to identify, select, and analyze relevant studies. Systematic reviews and meta-analyses provide the best evidence on",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to alternative beta-lactam/beta-lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol. The choice of combination therapy depends on several factors, including the specific microorganism, local epidemiology,",
                "Eravacycline is a new, lipid-complexed, long-acting tetracycline antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including those causing CRAB (Clostridioides difficile-associated diarrhea).\n\nSeveral studies have investigated the clinical efficacy of er",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a microRNA that plays a role in the regulation of Epstein-Barr virus (EBV) infection and immune response. Carrier status for EBV, including the presence of ESCR-E, does not directly increase the risk of postoperative infections in patients undergoing surgery, including liver transplant recipients. However, EBV infection can contribute to post-transplant lymphoproliferative disorder (PTLD),",
                "Preoperative screening for multidrug-resistant (MDR) Gram-negative bacteria (GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including the type of surgery, patient risk factors"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically an antimicrobial agent with activity against 3GCephRE, such as a carbapenem",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies, as well as through expert consensus. Guidelines, such as those from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations based on this evidence.",
                "Combination therapy is recommended for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. There are some data suggesting activity against certain CRAB strains, but more research is needed to fully understand its efficacy and safety in this indication.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09602691011282968,
                    "2_gram": 0.146996281591724,
                    "3_gram": 0.11204161068499845,
                    "4_gram": 0.08543503339025003
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.1901889599651231,
                        "recall": 0.43699387378375404,
                        "fmeasure": 0.2595630246071566
                    },
                    "rouge_L": {
                        "precision": 0.15065033147770754,
                        "recall": 0.35139797641691295,
                        "fmeasure": 0.20643396337957798
                    }
                },
                "METEOR": 0.2649717904667911,
                "BERTScore": {
                    "Precision": 0.024,
                    "Recall": 0.236,
                    "F1_measure": 0.129
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18243540063645156,
                    "2_gram": 0.28307715787390564,
                    "3_gram": 0.2609266904020759,
                    "4_gram": 0.21497888187040023
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4405971950543318,
                        "recall": 0.5378368797737075,
                        "fmeasure": 0.4186717589226639
                    },
                    "rouge_L": {
                        "precision": 0.3723728497402033,
                        "recall": 0.42556082171291987,
                        "fmeasure": 0.34745628403981155
                    }
                },
                "METEOR": 0.3794867315519773,
                "BERTScore": {
                    "Precision": 0.305,
                    "Recall": 0.418,
                    "F1_measure": 0.359
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamase (ESBL)-producing Klebsiella pneumoniae or other 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE), the recommended targeted therapy depends on",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on the available evidence from",
                "Eravacycline is a new fluorinated quinolone antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) infections in vitro and in animal models. However, the clinical evidence on the efficacy of eravacycline against CRAB infections in humans is still limited.\n\nA few small",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are commonly recommended for patients with bloodstream infections (BSIs) and severe infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "Combination therapy is recommended for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing and timing, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.102776863319113,
                    "2_gram": 0.15932851852220445,
                    "3_gram": 0.12840340156107338,
                    "4_gram": 0.10003017389086125
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2188868700672772,
                        "recall": 0.49642901227888353,
                        "fmeasure": 0.29866675955864
                    },
                    "rouge_L": {
                        "precision": 0.17593548183287006,
                        "recall": 0.40567115853057373,
                        "fmeasure": 0.24144695853740009
                    }
                },
                "METEOR": 0.289437070409042,
                "BERTScore": {
                    "Precision": -0.003,
                    "Recall": 0.279,
                    "F1_measure": 0.135
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.2180592678156384,
                    "2_gram": 0.31369098683724567,
                    "3_gram": 0.2701612111807909,
                    "4_gram": 0.22127301612720904
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4282856858566388,
                        "recall": 0.3742758031691527,
                        "fmeasure": 0.3663935682775887
                    },
                    "rouge_L": {
                        "precision": 0.3788307834605599,
                        "recall": 0.3285111322719261,
                        "fmeasure": 0.3237060970186888
                    }
                },
                "METEOR": 0.2719372433684724,
                "BERTScore": {
                    "Precision": 0.286,
                    "Recall": 0.371,
                    "F1_measure": 0.326
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamases (ESBLs) producing 3rd generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), the recommended targeted therapy is a carbapenem antibiotic. Car",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the National Institute for Health",
                "The recommendation for combination therapy in patients with carbapenem-resistant Enterobacterales (CRE) infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol depends on several factors, including the severity of the infection, the patient's clinical condition, and the local epidemiology of CRE.\n\nThe Infectious Diseases Society of America (IDSA) and the European Society of Clin",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad range of Gram-negative and Gram-positive bacteria, including those causing complex intra-abdominal infections (cIAI), including those caused by Carbapenem-resistant Acinetobacter baumannii (CRAB).",
                "ESCR-E (E-cadherin gene mutation causing E-cadherin loss of function, also known as Epithelial-to-Mesenchymal Transition-Ecadherin) carrier status is associated with an increased risk of postoperative infections, including infections after liver transplantation. E-cadherin is a key protein involved in maintaining the integrity of epithelial tissues, and its loss can lead to increased cellular mobility and susceptibility to bacterial invasion. Several studies have",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Study population: Define the study population based on patient characteristics, such as age, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as imipenem or meropenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3GCephalosporin-resistant Enterobacteriaceae (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for patients with severe infections or those at high risk for treatment failure. The specific agents and dosing regimens depend on the susceptibility patterns and patient factors. Consulting the most recent evidence-based guidelines and infect",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. No definitive conclusions have been made yet.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic regimen: Choice"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10146014881739525,
                    "2_gram": 0.15732299145906722,
                    "3_gram": 0.12424654166950466,
                    "4_gram": 0.0989483081194694
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.22111236769640982,
                        "recall": 0.514861965759557,
                        "fmeasure": 0.30383662524715394
                    },
                    "rouge_L": {
                        "precision": 0.16210708611761238,
                        "recall": 0.38066372419122,
                        "fmeasure": 0.22386491015715532
                    }
                },
                "METEOR": 0.3151098998778948,
                "BERTScore": {
                    "Precision": -0.013,
                    "Recall": 0.327,
                    "F1_measure": 0.152
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1799949404053738,
                    "2_gram": 0.26662512972905783,
                    "3_gram": 0.2338798748032822,
                    "4_gram": 0.19053804535426902
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.40711952140523566,
                        "recall": 0.5550729246570786,
                        "fmeasure": 0.4068286370298911
                    },
                    "rouge_L": {
                        "precision": 0.36211077639649064,
                        "recall": 0.4953380079497335,
                        "fmeasure": 0.36346521415866295
                    }
                },
                "METEOR": 0.3515533547674125,
                "BERTScore": {
                    "Precision": 0.306,
                    "Recall": 0.457,
                    "F1_measure": 0.377
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol. The goal of combination therapy is to increase the likelihood of microbiological and clinical success, reduce the risk of developing resistance, and decrease the emergence of superinfections.\n\nThe choice of",
                "Eravacycline is a new, lipid-linked, fluorinated tetracycline antibiotic that has shown activity against multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical efficacy of eravacycline against CRAB infections is still being investigated.\n\nSever",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including demographics, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in the current guidelines. However, the use of combination therapy is suggested for certain patient populations, such as those with severe infections or those at risk for treatment failure. The specific choice of agents for combination therapy depends on the susceptibility profile of the isolate and the patient's clinical condition",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.0967934765741134,
                    "2_gram": 0.15042081213477834,
                    "3_gram": 0.12059148444865674,
                    "4_gram": 0.09277436356388888
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20263646380858122,
                        "recall": 0.44593191347471,
                        "fmeasure": 0.2723359328869596
                    },
                    "rouge_L": {
                        "precision": 0.1635783492431857,
                        "recall": 0.3659786997160122,
                        "fmeasure": 0.22100510338590745
                    }
                },
                "METEOR": 0.27091116648599406,
                "BERTScore": {
                    "Precision": 0.024,
                    "Recall": 0.26,
                    "F1_measure": 0.14
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18237589812703145,
                    "2_gram": 0.2648975984515181,
                    "3_gram": 0.21926233897023434,
                    "4_gram": 0.17381870079040693
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3489510290581461,
                        "recall": 0.4445705877496516,
                        "fmeasure": 0.3407598966997463
                    },
                    "rouge_L": {
                        "precision": 0.30138905349122674,
                        "recall": 0.3992084933419579,
                        "fmeasure": 0.3002818676502887
                    }
                },
                "METEOR": 0.3015359558398559,
                "BERTScore": {
                    "Precision": 0.206,
                    "Recall": 0.382,
                    "F1_measure": 0.291
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. They use rigorous methods to identify, select, and analyze relevant studies. Systematic reviews and meta-analyses provide the best evidence on",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to alternative beta-lactam/beta-lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol. The choice of combination therapy depends on several factors, including the specific microorganism, local epidemiology,",
                "Eravacycline is a new, lipid-complexed, long-acting tetracycline antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including those causing CRAB (Clostridioides difficile-associated diarrhea).\n\nSeveral studies have investigated the clinical efficacy of er",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a microRNA that plays a role in the regulation of Epstein-Barr virus (EBV) infection and immune response. Carrier status for EBV, including the presence of ESCR-E, does not directly increase the risk of postoperative infections in patients undergoing surgery, including liver transplant recipients. However, EBV infection can contribute to post-transplant lymphoproliferative disorder (PTLD),",
                "Preoperative screening for multidrug-resistant (MDR) Gram-negative bacteria (GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including the type of surgery, patient risk factors"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically an antimicrobial agent with activity against 3GCephRE, such as a carbapenem",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies, as well as through expert consensus. Guidelines, such as those from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations based on this evidence.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting an infectious disease specialist is recommended for individualized treatment decisions.",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. There are some data suggesting activity against certain CRAB strains, but more research is needed to fully understand its efficacy and safety in this indication.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09602691011282968,
                    "2_gram": 0.146996281591724,
                    "3_gram": 0.11204161068499845,
                    "4_gram": 0.08543503339025003
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.1901889599651231,
                        "recall": 0.43699387378375404,
                        "fmeasure": 0.2595630246071566
                    },
                    "rouge_L": {
                        "precision": 0.15065033147770754,
                        "recall": 0.35139797641691295,
                        "fmeasure": 0.20643396337957798
                    }
                },
                "METEOR": 0.2649717904667911,
                "BERTScore": {
                    "Precision": 0.024,
                    "Recall": 0.236,
                    "F1_measure": 0.129
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.15212581445751372,
                    "2_gram": 0.23130806082921798,
                    "3_gram": 0.2003303708675115,
                    "4_gram": 0.15837144367184272
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.34943345683177013,
                        "recall": 0.5590009009377287,
                        "fmeasure": 0.37621958743823436
                    },
                    "rouge_L": {
                        "precision": 0.2831189663686728,
                        "recall": 0.43614283229493045,
                        "fmeasure": 0.3022810291871374
                    }
                },
                "METEOR": 0.37523194161448714,
                "BERTScore": {
                    "Precision": 0.243,
                    "Recall": 0.423,
                    "F1_measure": 0.33
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, combination therapy is recommended to increase the chances of successful treatment and reduce the risk of developing resistance.\n\nThe choice of antibiotics for combination therapy depends on the specific susceptibility patterns of the isolate and the clinical situation. Here are some",
                "Eravacycline is a new fluorinated quinolone antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). Several studies have reported the clinical efficacy of eravacycline against CRAB infections.\n\nA randomized",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection. The relationship between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients, is not well established.\n\nSome studies suggest that EBV reactivation and infection may increase the risk of postoperative complications, including infections, in liver transplant recipients. However, the evidence is",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for preoperative screening for MDR-",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically a carbapenem antibiotic.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "Combination therapy is recommended for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing and timing, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09522747210829219,
                    "2_gram": 0.14652880645616134,
                    "3_gram": 0.1185158820648661,
                    "4_gram": 0.09185287401725055
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2132583238574022,
                        "recall": 0.4896195782425141,
                        "fmeasure": 0.29157582190689996
                    },
                    "rouge_L": {
                        "precision": 0.16889434170540163,
                        "recall": 0.39192674831214447,
                        "fmeasure": 0.23164150321408686
                    }
                },
                "METEOR": 0.2946945554343169,
                "BERTScore": {
                    "Precision": 0.057,
                    "Recall": 0.289,
                    "F1_measure": 0.171
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.21237516626903627,
                    "2_gram": 0.3178216868538125,
                    "3_gram": 0.2813433179218076,
                    "4_gram": 0.23122697395273856
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.44032126932079363,
                        "recall": 0.42784723174058126,
                        "fmeasure": 0.3892967960489706
                    },
                    "rouge_L": {
                        "precision": 0.3704582036594086,
                        "recall": 0.3401570950048453,
                        "fmeasure": 0.32229509459348765
                    }
                },
                "METEOR": 0.32260327821602536,
                "BERTScore": {
                    "Precision": 0.278,
                    "Recall": 0.379,
                    "F1_measure": 0.326
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamases (ESBLs) producing 3rd generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), the recommended targeted therapy is a carbapenem antibiotic. Car",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the National Institute for Health",
                "The recommendation for combination therapy in patients with carbapenem-resistant Enterobacterales (CRE) infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol depends on several factors, including the severity of the infection, the patient's clinical condition, and the local epidemiology of CRE.\n\nThe Infectious Diseases Society of America (IDSA) and the European Society of Clin",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad range of Gram-negative and Gram-positive bacteria, including those causing complex intra-abdominal infections (cIAI), including those caused by Carbapenem-resistant Acinetobacter baumannii (CRAB).",
                "ESCR-E (E-cadherin gene mutation causing E-cadherin loss of function, also known as Epithelial-to-Mesenchymal Transition-Ecadherin) carrier status is associated with an increased risk of postoperative infections, including infections after surgery for liver transplantation. This increased risk is due to the loss of E-cadherin, which is a key protein in maintaining the integrity of epithelial cells and preventing bacterial invasion. The absence of E-",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Study population: Define the study population based on the specific surgical procedure, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as imipenem or meropenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3GCephalosporin-resistant Enterobacteriaceae (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for their quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for patients with severe infections or those at high risk for treatment failure. The specific agents and dosing regimens depend on the susceptibility patterns and patient factors. Consulting the most recent evidence-based guidelines and infect",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. No definitive conclusions have been made yet.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic regimen: Choice"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1013182041409144,
                    "2_gram": 0.15863134596482323,
                    "3_gram": 0.12586684159254669,
                    "4_gram": 0.09959428615086188
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21631565694615035,
                        "recall": 0.5113776452020657,
                        "fmeasure": 0.29857853051537503
                    },
                    "rouge_L": {
                        "precision": 0.16242630470041694,
                        "recall": 0.3841480447487113,
                        "fmeasure": 0.22469526888225091
                    }
                },
                "METEOR": 0.3124445775049563,
                "BERTScore": {
                    "Precision": -0.016,
                    "Recall": 0.324,
                    "F1_measure": 0.149
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.17945782228821697,
                    "2_gram": 0.2658133365887098,
                    "3_gram": 0.23330976821813804,
                    "4_gram": 0.1901384158441274
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4057589771875486,
                        "recall": 0.5550729246570786,
                        "fmeasure": 0.4059782968938367
                    },
                    "rouge_L": {
                        "precision": 0.3607502321788036,
                        "recall": 0.4953380079497335,
                        "fmeasure": 0.36261487402260856
                    }
                },
                "METEOR": 0.35136448858776426,
                "BERTScore": {
                    "Precision": 0.306,
                    "Recall": 0.456,
                    "F1_measure": 0.377
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infection caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol. The goal of combination therapy is to increase the likelihood of microbiological and clinical success, reduce the risk of developing resistance, and decrease the emergence of adverse events.\n\nThe Infect",
                "Eravacycline is a new, lipid-linked, broad-spectrum tetracycline antibiotic that has shown activity against multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical efficacy of eravacycline against CRAB infections is still being investigated.\n\nS",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-encoded microRNAs) carrier status is not directly associated with an increased risk of postoperative infections in patients undergoing surgery, including liver transplant recipients. However, there is some evidence suggesting that EBV reactivation may contribute to the development of post-transplant lymphoproliferative disorder (PTLD), a type of cancer that can occur in immunocompromised individuals, including liver transplant recipients. PTLD is characterized",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: The patient population should be well-defined, including demographic information, com"
            ],
            "additional prompt / finetuning": [
                "Monotherapy with a carbapenem antibiotic is typically recommended.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy may not be sufficient. The choice of agents for combination therapy depends on the specific susceptibility patterns of the isolate and local resistance patterns. Consulting an infectious disease specialist",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09388311063219405,
                    "2_gram": 0.15028338573609518,
                    "3_gram": 0.11999084827927689,
                    "4_gram": 0.09255497062453745
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20044763335791976,
                        "recall": 0.46974143728423384,
                        "fmeasure": 0.27528734946681543
                    },
                    "rouge_L": {
                        "precision": 0.16249616782044704,
                        "recall": 0.3813677821782654,
                        "fmeasure": 0.22331107989931118
                    }
                },
                "METEOR": 0.29245543707196303,
                "BERTScore": {
                    "Precision": 0.027,
                    "Recall": 0.261,
                    "F1_measure": 0.142
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.21108569520618023,
                    "2_gram": 0.28502729836890256,
                    "3_gram": 0.2341259545503361,
                    "4_gram": 0.1873780320556306
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3685698378010143,
                        "recall": 0.4267134448925087,
                        "fmeasure": 0.35160802816012265
                    },
                    "rouge_L": {
                        "precision": 0.3208976116897328,
                        "recall": 0.38135135048481505,
                        "fmeasure": 0.31101338103486326
                    }
                },
                "METEOR": 0.3041059642037072,
                "BERTScore": {
                    "Precision": 0.288,
                    "Recall": 0.383,
                    "F1_measure": 0.334
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. They use rigorous methods to identify, select, and analyze relevant studies. Systematic reviews and meta-analyses provide the best evidence on",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to alternative beta-lactam/beta-lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol. The choice of combination therapy depends on several factors, including the specific microorganism, local epidemiology,",
                "Eravacycline is a new, lipid-complexed, intravenously administered fluorinated quinolone antibiotic that has shown promise against Carbapenem-resistant Acinetobacter baumannii (CRAB) infections. However, the clinical evidence on its efficacy is still limited and primarily comes from small, single-center studies.\n\nOne",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a microRNA that plays a role in the regulation of Epstein-Barr virus (EBV) infection. EBV is a double-stranded DNA virus that is associated with various human diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nCarrier status for EBV refers to the presence of the",
                "Preoperative screening for multidrug-resistant (MDR) Gram-negative bacteria (GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of advanced diagnostic tools: There is a need for more accurate and rapid diagnostic tools for",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including the type of surgery, patient risk factors"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically an antimicrobial agent with activity against 3GCephRE, such as a carbapenem",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies, as well as through expert consensus. Guidelines, such as those from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations based on this evidence.",
                "Combination therapy is recommended for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. There are some data suggesting activity against certain CRAB strains, but more research is needed to determine its overall effectiveness and safety.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Type of surgery: Selection of specific surgical procedures with high"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09719349498259097,
                    "2_gram": 0.151463535009904,
                    "3_gram": 0.10898731412536514,
                    "4_gram": 0.07904351536493974
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.1814858751433015,
                        "recall": 0.4222991305630299,
                        "fmeasure": 0.24828405210400792
                    },
                    "rouge_L": {
                        "precision": 0.13477870363897831,
                        "recall": 0.32625027152371494,
                        "fmeasure": 0.1867063440977285
                    }
                },
                "METEOR": 0.23279647443162052,
                "BERTScore": {
                    "Precision": -0.017,
                    "Recall": 0.201,
                    "F1_measure": 0.09
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18189206551949222,
                    "2_gram": 0.2836520933765659,
                    "3_gram": 0.2619799560101361,
                    "4_gram": 0.2151501866472198
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.44117593045793424,
                        "recall": 0.5378368797737075,
                        "fmeasure": 0.41806052935621046
                    },
                    "rouge_L": {
                        "precision": 0.3723593538528765,
                        "recall": 0.42556082171291987,
                        "fmeasure": 0.34646876133587096
                    }
                },
                "METEOR": 0.38234182127249683,
                "BERTScore": {
                    "Precision": 0.309,
                    "Recall": 0.414,
                    "F1_measure": 0.359
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum \u03b2-lactamases producing Cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility profile",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, combination therapy is recommended to increase the chances of successful treatment and reduce the risk of developing resistance.\n\nThe choice of antibiotics for combination therapy depends on the specific susceptibility patterns of the isolate and the clinical situation. Here are some",
                "Eravacycline is a new fluorinated quinolone antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). Several studies have reported the clinical efficacy of eravacycline against CRAB infections.\n\nA randomized",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection. The relationship between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients, is not well established.\n\nSome studies suggest that EBV reactivation and infection may increase the risk of postoperative complications, including infections, in liver transplant recipients. However, the evidence is",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for preoperative screening for MDR-",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically a carbapenem antibiotic.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "Combination therapy is recommended for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing and timing, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09585009403842018,
                    "2_gram": 0.14707741299555127,
                    "3_gram": 0.11837031348803573,
                    "4_gram": 0.0920913107202538
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21397982457890294,
                        "recall": 0.4896195782425141,
                        "fmeasure": 0.2925260911498522
                    },
                    "rouge_L": {
                        "precision": 0.1696158424269023,
                        "recall": 0.39192674831214447,
                        "fmeasure": 0.23259177245703905
                    }
                },
                "METEOR": 0.2954448555543649,
                "BERTScore": {
                    "Precision": 0.055,
                    "Recall": 0.29,
                    "F1_measure": 0.171
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.21237516626903627,
                    "2_gram": 0.3178216868538125,
                    "3_gram": 0.2813433179218076,
                    "4_gram": 0.23122697395273856
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.44032126932079363,
                        "recall": 0.42784723174058126,
                        "fmeasure": 0.3892967960489706
                    },
                    "rouge_L": {
                        "precision": 0.3704582036594086,
                        "recall": 0.3401570950048453,
                        "fmeasure": 0.32229509459348765
                    }
                },
                "METEOR": 0.32260327821602536,
                "BERTScore": {
                    "Precision": 0.278,
                    "Recall": 0.379,
                    "F1_measure": 0.326
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamases (ESBLs) producing 3rd generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), the recommended targeted therapy is a carbapenem antibiotic. Car",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the National Institute for Health",
                "The recommendation for combination therapy in patients with carbapenem-resistant Enterobacterales (CRE) infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol depends on several factors, including the severity of the infection, the patient's clinical condition, and the local epidemiology of CRE.\n\nThe Infectious Diseases Society of America (IDSA) and the European Society of Clin",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad range of Gram-negative and Gram-positive bacteria, including those causing complex intra-abdominal infections (cIAI), including those caused by Carbapenem-resistant Acinetobacter baumannii (CRAB).",
                "ESCR-E (E-cadherin gene mutation causing E-cadherin loss of function, also known as Epithelial-to-Mesenchymal Transition-Ecadherin) carrier status is associated with an increased risk of postoperative infections, including infections after surgery for liver transplantation. This increased risk is due to the loss of E-cadherin, which is a key protein in maintaining the integrity of epithelial cells and preventing bacterial invasion. The absence of E-",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Study population: Define the study population based on the specific surgical procedure, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as imipenem or meropenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3GCephalosporin-resistant Enterobacteriaceae (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for their quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for patients with severe infections or those at high risk for treatment failure. The specific agents and dosing regimens depend on the susceptibility patterns and patient factors. Consulting the most recent evidence-based guidelines and infect",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. No definitive conclusions have been made yet.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic regimen: Choice"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1013182041409144,
                    "2_gram": 0.15863134596482323,
                    "3_gram": 0.12586684159254669,
                    "4_gram": 0.09959428615086188
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21631565694615035,
                        "recall": 0.5113776452020657,
                        "fmeasure": 0.29857853051537503
                    },
                    "rouge_L": {
                        "precision": 0.16242630470041694,
                        "recall": 0.3841480447487113,
                        "fmeasure": 0.22469526888225091
                    }
                },
                "METEOR": 0.3124445775049563,
                "BERTScore": {
                    "Precision": -0.016,
                    "Recall": 0.324,
                    "F1_measure": 0.149
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.17945782228821697,
                    "2_gram": 0.2658133365887098,
                    "3_gram": 0.23330976821813804,
                    "4_gram": 0.1901384158441274
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4057589771875486,
                        "recall": 0.5550729246570786,
                        "fmeasure": 0.4059782968938367
                    },
                    "rouge_L": {
                        "precision": 0.3607502321788036,
                        "recall": 0.4953380079497335,
                        "fmeasure": 0.36261487402260856
                    }
                },
                "METEOR": 0.35136448858776426,
                "BERTScore": {
                    "Precision": 0.306,
                    "Recall": 0.456,
                    "F1_measure": 0.377
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infection caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol. The goal of combination therapy is to increase the likelihood of microbiological and clinical success, reduce the risk of developing resistance, and decrease the emergence of adverse events.\n\nThe Infect",
                "Eravacycline is a new, lipid-linked, broad-spectrum tetracycline antibiotic that has shown activity against multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical efficacy of eravacycline against CRAB infections is still being investigated.\n\nS",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-encoded microRNAs) carrier status is not directly associated with an increased risk of postoperative infections in patients undergoing surgery, including liver transplant recipients. However, there is some evidence suggesting that EBV reactivation may contribute to the development of post-transplant lymphoproliferative disorder (PTLD), a type of cancer that can occur in immunocompromised individuals, including liver transplant recipients. PTLD is characterized",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: The patient population should be well-defined, including demographic information, com"
            ],
            "additional prompt / finetuning": [
                "Monotherapy with a carbapenem antibiotic is typically recommended.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy may not be sufficient. The choice of agents for combination therapy depends on the specific susceptibility patterns of the isolate and local resistance patterns. Consulting an infectious disease specialist",
                "The current evidence shows that eravacycline is effective against CRAB (complex multidrug-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09388311063219405,
                    "2_gram": 0.15028338573609518,
                    "3_gram": 0.11999084827927689,
                    "4_gram": 0.09255497062453745
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20044763335791976,
                        "recall": 0.46974143728423384,
                        "fmeasure": 0.27528734946681543
                    },
                    "rouge_L": {
                        "precision": 0.16249616782044704,
                        "recall": 0.3813677821782654,
                        "fmeasure": 0.22331107989931118
                    }
                },
                "METEOR": 0.29245543707196303,
                "BERTScore": {
                    "Precision": 0.027,
                    "Recall": 0.261,
                    "F1_measure": 0.142
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.21019813087812342,
                    "2_gram": 0.28124918990329406,
                    "3_gram": 0.2323631152037619,
                    "4_gram": 0.18606522623154656
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36559364732482386,
                        "recall": 0.4267134448925087,
                        "fmeasure": 0.35064407982775325
                    },
                    "rouge_L": {
                        "precision": 0.3179214212135424,
                        "recall": 0.38135135048481505,
                        "fmeasure": 0.3100494327024939
                    }
                },
                "METEOR": 0.30404772885135417,
                "BERTScore": {
                    "Precision": 0.289,
                    "Recall": 0.383,
                    "F1_measure": 0.334
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 8,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. They use rigorous methods to identify, select, and analyze relevant studies. Systematic reviews and meta-analyses provide the best evidence on",
                "Combination therapy is often considered in the treatment of complicated or severe infections caused by Carbapenem-resistant Enterobacterales (CRE), including those susceptible to alternative beta-lactam/beta-lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol. The choice of combination therapy depends on several factors, including the specific microorganism, local epidemiology,",
                "Eravacycline is a new, lipid-complexed, intravenously administered fluorinated quinolone antibiotic that has shown promise against Carbapenem-resistant Acinetobacter baumannii (CRAB) infections. However, the clinical evidence on its efficacy is still limited and primarily comes from small, single-center studies.\n\nOne",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a microRNA that plays a role in the regulation of Epstein-Barr virus (EBV) infection. EBV is a double-stranded DNA virus that is associated with various human diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nCarrier status for EBV refers to the presence of the",
                "Preoperative screening for multidrug-resistant (MDR) Gram-negative bacteria (GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of advanced diagnostic tools: There is a need for more accurate and rapid diagnostic tools for",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including the type of surgery, patient risk factors"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically an antimicrobial agent with activity against 3GCephRE, such as a carbapenem",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are assessed for quality and relevance to inform recommendations.",
                "Combination therapy is recommended for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.",
                "The current evidence on the clinical efficacy of eravacycline against CRAB infections is still being studied in clinical trials. There are some data suggesting activity against certain CRAB strains, but more research is needed to determine its overall effectiveness and safety.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Type of surgery: Selection of specific surgical procedures with high"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09719349498259097,
                    "2_gram": 0.151463535009904,
                    "3_gram": 0.10898731412536514,
                    "4_gram": 0.07904351536493974
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.1814858751433015,
                        "recall": 0.4222991305630299,
                        "fmeasure": 0.24828405210400792
                    },
                    "rouge_L": {
                        "precision": 0.13477870363897831,
                        "recall": 0.32625027152371494,
                        "fmeasure": 0.1867063440977285
                    }
                },
                "METEOR": 0.23279647443162052,
                "BERTScore": {
                    "Precision": -0.017,
                    "Recall": 0.201,
                    "F1_measure": 0.09
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18921356730593866,
                    "2_gram": 0.29589997267780943,
                    "3_gram": 0.2723197156712409,
                    "4_gram": 0.22255198882514135
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4607435276117383,
                        "recall": 0.5378368797737075,
                        "fmeasure": 0.4329068748711606
                    },
                    "rouge_L": {
                        "precision": 0.39192695100668057,
                        "recall": 0.42556082171291987,
                        "fmeasure": 0.3613151068508212
                    }
                },
                "METEOR": 0.4028341017121952,
                "BERTScore": {
                    "Precision": 0.323,
                    "Recall": 0.404,
                    "F1_measure": 0.361
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:\n\n1. Car",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend using these agents as monotherapy, if possible, due to their pot",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative and some Gram-positive bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). Several in vitro studies have demonstrated the activity of eravacycline against CRAB isolates",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are commonly recommended for patients with bloodstream infections (BSIs) and severe infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is suggested for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting infectious disease specialists is recommended for individualized treatment plans.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing and timing, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10033142311980955,
                    "2_gram": 0.15391038175019997,
                    "3_gram": 0.11750996736612307,
                    "4_gram": 0.08874838871154657
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20225655200286563,
                        "recall": 0.4662932864909838,
                        "fmeasure": 0.2761789197157152
                    },
                    "rouge_L": {
                        "precision": 0.1628918471553639,
                        "recall": 0.38266678770011603,
                        "fmeasure": 0.22373332458808406
                    }
                },
                "METEOR": 0.26271266196406534,
                "BERTScore": {
                    "Precision": 0.005,
                    "Recall": 0.269,
                    "F1_measure": 0.134
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18965209193715696,
                    "2_gram": 0.26658429974418485,
                    "3_gram": 0.21506125401742318,
                    "4_gram": 0.16849542226762712
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3384747614868909,
                        "recall": 0.3954398243331738,
                        "fmeasure": 0.32529181289011905
                    },
                    "rouge_L": {
                        "precision": 0.29072679186392125,
                        "recall": 0.3390931428539367,
                        "fmeasure": 0.2796786958484305
                    }
                },
                "METEOR": 0.2681887299215122,
                "BERTScore": {
                    "Precision": 0.216,
                    "Recall": 0.374,
                    "F1_measure": 0.293
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that is approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, including those caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrying the EBV virus does not necessarily mean that a person will develop postoperative infections.",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as imipenem or meropenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the effectiveness and safety of various treatment options, including antibiotics and combination therapies. The evidence is then graded based on its quality and certainty, and recommendations for treatment are made based on this evidence.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical situation and microbiological data.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on surgical site, risk factors, and microbiological considerations.\n2. Antibiotic selection: Choice"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09904559111887455,
                    "2_gram": 0.1518819998369548,
                    "3_gram": 0.11363747545651824,
                    "4_gram": 0.08239624878821432
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.17593984393239204,
                        "recall": 0.40014760469994526,
                        "fmeasure": 0.2378824950253522
                    },
                    "rouge_L": {
                        "precision": 0.13730808719965965,
                        "recall": 0.3193078810409518,
                        "fmeasure": 0.18696262981977266
                    }
                },
                "METEOR": 0.21944176146336064,
                "BERTScore": {
                    "Precision": -0.059,
                    "Recall": 0.173,
                    "F1_measure": 0.056
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.20320268834401076,
                    "2_gram": 0.2901542172793121,
                    "3_gram": 0.2528394933567878,
                    "4_gram": 0.206149732069751
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4044899544899545,
                        "recall": 0.5156212302288654,
                        "fmeasure": 0.3916096741726994
                    },
                    "rouge_L": {
                        "precision": 0.3609818752675896,
                        "recall": 0.4639041783792579,
                        "fmeasure": 0.3516436877781416
                    }
                },
                "METEOR": 0.30346128465747674,
                "BERTScore": {
                    "Precision": 0.346,
                    "Recall": 0.452,
                    "F1_measure": 0.396
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy is usually an antimicrobial agent active against these bacteria. Here are some options:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited and mainly comes from small, open-label studies.",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the efficacy and safety of various antibiotics for treating 3GCephRE infections. The results are then synthesized to provide evidence-based recommendations for clinical practice.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for CRE infections due to the high risk of treatment failure with monotherapy. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting the most recent evidence-based guidelines",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10133811115248423,
                    "2_gram": 0.15790457116520934,
                    "3_gram": 0.12048308140774802,
                    "4_gram": 0.09042865618923837
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2103504313221402,
                        "recall": 0.46650118749043157,
                        "fmeasure": 0.28307729181404945
                    },
                    "rouge_L": {
                        "precision": 0.1522711434716383,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20718327837332956
                    }
                },
                "METEOR": 0.2702748366386142,
                "BERTScore": {
                    "Precision": -0.019,
                    "Recall": 0.218,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1616192253144259,
                    "2_gram": 0.23876278307253312,
                    "3_gram": 0.20442492036158041,
                    "4_gram": 0.16491599987528718
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.35283727391955716,
                        "recall": 0.5501277864745521,
                        "fmeasure": 0.37604748992504095
                    },
                    "rouge_L": {
                        "precision": 0.29034950620701977,
                        "recall": 0.4449830833712064,
                        "fmeasure": 0.30876121610815493
                    }
                },
                "METEOR": 0.31527707579613207,
                "BERTScore": {
                    "Precision": 0.263,
                    "Recall": 0.428,
                    "F1_measure": 0.342
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical efficacy of eravacycline against CRAB infections is still being investigated.\n\nA few small studies have reported promising results. For",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients undergoing",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including demographics, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for CRE infections due to the risk of developing resistance during monotherapy. The specific agents and combinations should be determined based on the patient's individual clinical situation and susceptibility testing results. Consulting infectious disease specialists",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing liver transplant surgery.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1012062963824504,
                    "2_gram": 0.15848632411373403,
                    "3_gram": 0.12410246832226057,
                    "4_gram": 0.09521074800349272
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21751007610437254,
                        "recall": 0.4637743279236992,
                        "fmeasure": 0.28951361139394244
                    },
                    "rouge_L": {
                        "precision": 0.16501958356897495,
                        "recall": 0.3608167433345436,
                        "fmeasure": 0.22124618918704977
                    }
                },
                "METEOR": 0.28216153813695877,
                "BERTScore": {
                    "Precision": 0.004,
                    "Recall": 0.251,
                    "F1_measure": 0.125
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.20195660347159314,
                    "2_gram": 0.2842974188829273,
                    "3_gram": 0.23601530637363283,
                    "4_gram": 0.18691310686480359
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36591250854408747,
                        "recall": 0.43760194663466895,
                        "fmeasure": 0.3403191503636454
                    },
                    "rouge_L": {
                        "precision": 0.3233775998437653,
                        "recall": 0.39572417278446664,
                        "fmeasure": 0.3039021515062207
                    }
                },
                "METEOR": 0.30240924386494417,
                "BERTScore": {
                    "Precision": 0.285,
                    "Recall": 0.382,
                    "F1_measure": 0.331
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:\n\n1. Car",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend using these agents as monotherapy, if possible, due to their pot",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative and some Gram-positive bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). Several in vitro studies have demonstrated the activity of eravacycline against CRAB isolates",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are commonly recommended for patients with bloodstream infections (BSIs) and severe infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is suggested for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting infectious disease specialists is recommended for individualized treatment plans.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing and timing, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10033142311980955,
                    "2_gram": 0.15391038175019997,
                    "3_gram": 0.11750996736612307,
                    "4_gram": 0.08874838871154657
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20225655200286563,
                        "recall": 0.4662932864909838,
                        "fmeasure": 0.2761789197157152
                    },
                    "rouge_L": {
                        "precision": 0.1628918471553639,
                        "recall": 0.38266678770011603,
                        "fmeasure": 0.22373332458808406
                    }
                },
                "METEOR": 0.26271266196406534,
                "BERTScore": {
                    "Precision": 0.005,
                    "Recall": 0.269,
                    "F1_measure": 0.134
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18965209193715696,
                    "2_gram": 0.26658429974418485,
                    "3_gram": 0.21506125401742318,
                    "4_gram": 0.16849542226762712
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3384747614868909,
                        "recall": 0.3954398243331738,
                        "fmeasure": 0.32529181289011905
                    },
                    "rouge_L": {
                        "precision": 0.29072679186392125,
                        "recall": 0.3390931428539367,
                        "fmeasure": 0.2796786958484305
                    }
                },
                "METEOR": 0.2681887299215122,
                "BERTScore": {
                    "Precision": 0.216,
                    "Recall": 0.374,
                    "F1_measure": 0.293
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that is approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, including those caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a common human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients under",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as imipenem or meropenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the effectiveness and safety of various treatment options, including antibiotics and combination therapies. The evidence is then graded based on its quality and certainty, and recommendations for treatment are made based on this evidence.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical situation and microbiological data.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on surgical site, risk factors, and microbiological considerations.\n2. Antibiotic selection: Choice"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09907433518605555,
                    "2_gram": 0.15242121552322935,
                    "3_gram": 0.11714659926639392,
                    "4_gram": 0.08530134428681925
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.1857920606811605,
                        "recall": 0.4140848869299104,
                        "fmeasure": 0.24942650656936372
                    },
                    "rouge_L": {
                        "precision": 0.144697249761236,
                        "recall": 0.32976084271342565,
                        "fmeasure": 0.1956206384777813
                    }
                },
                "METEOR": 0.2404520720268201,
                "BERTScore": {
                    "Precision": -0.046,
                    "Recall": 0.19,
                    "F1_measure": 0.07
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.19926168886729698,
                    "2_gram": 0.29073901260094953,
                    "3_gram": 0.2526516582418668,
                    "4_gram": 0.20484055737347953
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.4044899544899545,
                        "recall": 0.5156212302288654,
                        "fmeasure": 0.3916096741726994
                    },
                    "rouge_L": {
                        "precision": 0.3609818752675896,
                        "recall": 0.4639041783792579,
                        "fmeasure": 0.3516436877781416
                    }
                },
                "METEOR": 0.30346128465747674,
                "BERTScore": {
                    "Precision": 0.344,
                    "Recall": 0.448,
                    "F1_measure": 0.393
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy is usually an antimicrobial agent active against these bacteria. Here are some options:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited and mainly comes from small, open-label studies.",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population for the trial, including age, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized in evidence-based guidelines, which provide recommendations based on a systematic review of the available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the diagnosis, management, and prevention of 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for CRE infections due to the high risk of treatment failure with monotherapy. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting the most recent evidence-based guidelines",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10210718623849921,
                    "2_gram": 0.15903791924128188,
                    "3_gram": 0.12145678126220552,
                    "4_gram": 0.09110063383713976
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2133802752851761,
                        "recall": 0.46650118749043157,
                        "fmeasure": 0.2867951094550942
                    },
                    "rouge_L": {
                        "precision": 0.15454352644391522,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20997164160411308
                    }
                },
                "METEOR": 0.27176775739895426,
                "BERTScore": {
                    "Precision": -0.016,
                    "Recall": 0.219,
                    "F1_measure": 0.1
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.16161638543801732,
                    "2_gram": 0.23707003211911185,
                    "3_gram": 0.20030645075657474,
                    "4_gram": 0.16238939262427046
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3499801310624142,
                        "recall": 0.5450257456582255,
                        "fmeasure": 0.37238448626203724
                    },
                    "rouge_L": {
                        "precision": 0.2874923633498768,
                        "recall": 0.43988104255487986,
                        "fmeasure": 0.30509821244515123
                    }
                },
                "METEOR": 0.3020342015558967,
                "BERTScore": {
                    "Precision": 0.263,
                    "Recall": 0.431,
                    "F1_measure": 0.344
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical efficacy of eravacycline against CRAB infections is still being investigated.\n\nA few small studies have reported promising results. For",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients undergoing",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including demographics, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for CRE infections due to the risk of developing resistance during monotherapy. The specific agents and combinations should be determined based on the patient's individual clinical situation and susceptibility testing results. Consulting infectious disease specialists",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing liver transplant surgery.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1012062963824504,
                    "2_gram": 0.15848632411373403,
                    "3_gram": 0.12410246832226057,
                    "4_gram": 0.09521074800349272
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21751007610437254,
                        "recall": 0.4637743279236992,
                        "fmeasure": 0.28951361139394244
                    },
                    "rouge_L": {
                        "precision": 0.16501958356897495,
                        "recall": 0.3608167433345436,
                        "fmeasure": 0.22124618918704977
                    }
                },
                "METEOR": 0.28216153813695877,
                "BERTScore": {
                    "Precision": 0.004,
                    "Recall": 0.251,
                    "F1_measure": 0.125
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.16880930613262732,
                    "2_gram": 0.24613163405047583,
                    "3_gram": 0.20591326555730632,
                    "4_gram": 0.16378609480664544
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3366917293233082,
                        "recall": 0.45623548700733974,
                        "fmeasure": 0.33986078519939783
                    },
                    "rouge_L": {
                        "precision": 0.2852282491944146,
                        "recall": 0.40193535290869026,
                        "fmeasure": 0.29305417595236277
                    }
                },
                "METEOR": 0.310311487331138,
                "BERTScore": {
                    "Precision": 0.236,
                    "Recall": 0.368,
                    "F1_measure": 0.3
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend using a beta-lactam/beta-lactamase",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against some multidrug-resistant bacteria, including Carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical efficacy of eravacycline against CRAB infections is still being studied, and there",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nThere is limited evidence regarding the association between ESCR-E carrier status and post",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy fails. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting infectious disease specialists and microbiology laboratories is",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing regimens, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10309297969423814,
                    "2_gram": 0.1533574366125608,
                    "3_gram": 0.12038574217517652,
                    "4_gram": 0.09107107986382912
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20814883809399617,
                        "recall": 0.4469212216523229,
                        "fmeasure": 0.2769516559877349
                    },
                    "rouge_L": {
                        "precision": 0.16453645987142065,
                        "recall": 0.36056786329472285,
                        "fmeasure": 0.2204332467774103
                    }
                },
                "METEOR": 0.2640141450194009,
                "BERTScore": {
                    "Precision": -0.012,
                    "Recall": 0.236,
                    "F1_measure": 0.11
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18803461927023543,
                    "2_gram": 0.26581336376046366,
                    "3_gram": 0.21912135206070693,
                    "4_gram": 0.1724676892545142
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.34551250820951157,
                        "recall": 0.4258631047564543,
                        "fmeasure": 0.3371116584149165
                    },
                    "rouge_L": {
                        "precision": 0.2998522860787012,
                        "recall": 0.3748074285682224,
                        "fmeasure": 0.2945170767225905
                    }
                },
                "METEOR": 0.29470760683649333,
                "BERTScore": {
                    "Precision": 0.214,
                    "Recall": 0.384,
                    "F1_measure": 0.297
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that is approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, including those caused by susceptible strains of carbapenem-resistant Acinetobacter baumannii (CRAB).\n\nSeveral",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a common human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients under",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for their quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical situation and microbiological data.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10093576130887162,
                    "2_gram": 0.15407210027094972,
                    "3_gram": 0.11898383020294441,
                    "4_gram": 0.08602491210994093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.19044308251547076,
                        "recall": 0.42029606705413397,
                        "fmeasure": 0.25491041280514964
                    },
                    "rouge_L": {
                        "precision": 0.14550694470839726,
                        "recall": 0.32976084271342565,
                        "fmeasure": 0.19633220761040307
                    }
                },
                "METEOR": 0.24058701276269628,
                "BERTScore": {
                    "Precision": -0.034,
                    "Recall": 0.199,
                    "F1_measure": 0.081
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.19260731320848054,
                    "2_gram": 0.28026104427537213,
                    "3_gram": 0.2357541062754527,
                    "4_gram": 0.18842554247230353
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.37786880621467084,
                        "recall": 0.43398857716764094,
                        "fmeasure": 0.36272134794691185
                    },
                    "rouge_L": {
                        "precision": 0.34045655263700375,
                        "recall": 0.4001286681751763,
                        "fmeasure": 0.3311444649414574
                    }
                },
                "METEOR": 0.3096219151329693,
                "BERTScore": {
                    "Precision": 0.239,
                    "Recall": 0.387,
                    "F1_measure": 0.311
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive studies that aim to collate and analyze all relevant studies on a particular topic. Systematic reviews and meta-analyses provide a synthesized view of the available evidence and help to identify trends",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend the use of a beta-lactam/beta-lactamase inhibitor",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited and mainly comes from small, open-label studies.",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population for the trial, including age, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for CRE infections due to the high risk of treatment failure with monotherapy. The specific combination regimens and duration of therapy depend on the patient's clinical condition, infection site, and susceptibility patterns. Consult",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10223700977090125,
                    "2_gram": 0.15792098807474866,
                    "3_gram": 0.12055002293853967,
                    "4_gram": 0.09015118504845761
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21188464871984478,
                        "recall": 0.4613991466741049,
                        "fmeasure": 0.2839308296716341
                    },
                    "rouge_L": {
                        "precision": 0.157464388940235,
                        "recall": 0.3556547869530751,
                        "fmeasure": 0.21340618929595107
                    }
                },
                "METEOR": 0.2666020173793365,
                "BERTScore": {
                    "Precision": -0.006,
                    "Recall": 0.226,
                    "F1_measure": 0.108
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.16446104380033236,
                    "2_gram": 0.24770573361328183,
                    "3_gram": 0.20768901306744195,
                    "4_gram": 0.16565171313779856
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3583516660252618,
                        "recall": 0.5346326995508937,
                        "fmeasure": 0.3771630257344543
                    },
                    "rouge_L": {
                        "precision": 0.2964712918660287,
                        "recall": 0.42948799644754804,
                        "fmeasure": 0.3099071183281709
                    }
                },
                "METEOR": 0.318185847193223,
                "BERTScore": {
                    "Precision": 0.268,
                    "Recall": 0.422,
                    "F1_measure": 0.342
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor combination as",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against some multidrug-resistant bacteria, including Carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a microRNA that plays a role in the regulation of Epstein-Barr virus (EBV) infection and lymphomagenesis. However, there is limited evidence regarding the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients.\n\nSome studies suggest that EBV infection may increase the risk of postoperative infections in liver transplant recipients. For",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including demographics, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider adding an aminoglycoside or polymyxin.",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09886448627418355,
                    "2_gram": 0.15560200595017334,
                    "3_gram": 0.1277008100360382,
                    "4_gram": 0.09932803582436353
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.22773642332567015,
                        "recall": 0.49072871755041125,
                        "fmeasure": 0.3055683172445667
                    },
                    "rouge_L": {
                        "precision": 0.17357202056207882,
                        "recall": 0.3817226666794914,
                        "fmeasure": 0.23413035717325853
                    }
                },
                "METEOR": 0.30595984354401345,
                "BERTScore": {
                    "Precision": 0.038,
                    "Recall": 0.273,
                    "F1_measure": 0.154
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.19196349935276164,
                    "2_gram": 0.28605618226924284,
                    "3_gram": 0.2565048147841222,
                    "4_gram": 0.2142110163669615
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.407256878459886,
                        "recall": 0.4438467916918151,
                        "fmeasure": 0.37769127804670777
                    },
                    "rouge_L": {
                        "precision": 0.3527932239022465,
                        "recall": 0.394837662884171,
                        "fmeasure": 0.3310673008950683
                    }
                },
                "METEOR": 0.3201918211418316,
                "BERTScore": {
                    "Precision": 0.266,
                    "Recall": 0.371,
                    "F1_measure": 0.316
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend using a beta-lactam/beta-lactamase",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against some multidrug-resistant bacteria, including Carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical efficacy of eravacycline against CRAB infections is still being studied, and there",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nThere is limited evidence regarding the association between ESCR-E carrier status and post",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population based on specific surgical procedures, patient risk factors,"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy fails. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting infectious disease specialists and microbiology laboratories is",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "Factors to consider when designing clinical trials of targeted PAP include patient population, type and duration of surgery, choice of antibiotics, dosing regimens, and outcome measures."
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1032454012923786,
                    "2_gram": 0.1535820095474141,
                    "3_gram": 0.12057864340974443,
                    "4_gram": 0.0912041804559881
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2087528852096712,
                        "recall": 0.4469212216523229,
                        "fmeasure": 0.2776937710155642
                    },
                    "rouge_L": {
                        "precision": 0.1649894952081769,
                        "recall": 0.36056786329472285,
                        "fmeasure": 0.2209898330482823
                    }
                },
                "METEOR": 0.2643126511170548,
                "BERTScore": {
                    "Precision": -0.013,
                    "Recall": 0.237,
                    "F1_measure": 0.11
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18803461927023543,
                    "2_gram": 0.26581336376046366,
                    "3_gram": 0.21912135206070693,
                    "4_gram": 0.1724676892545142
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.34551250820951157,
                        "recall": 0.4258631047564543,
                        "fmeasure": 0.3371116584149165
                    },
                    "rouge_L": {
                        "precision": 0.2998522860787012,
                        "recall": 0.3748074285682224,
                        "fmeasure": 0.2945170767225905
                    }
                },
                "METEOR": 0.29470760683649333,
                "BERTScore": {
                    "Precision": 0.214,
                    "Recall": 0.384,
                    "F1_measure": 0.297
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that is approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, including those caused by susceptible strains of carbapenem-resistant Acinetobacter baumannii (CRAB).\n\nSeveral",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a common human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nRegarding the association between ESCR-E carrier status and postoperative infections in patients under",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for their quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical situation and microbiological data.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10093576130887162,
                    "2_gram": 0.15407210027094972,
                    "3_gram": 0.11898383020294441,
                    "4_gram": 0.08602491210994093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.19044308251547076,
                        "recall": 0.42029606705413397,
                        "fmeasure": 0.25491041280514964
                    },
                    "rouge_L": {
                        "precision": 0.14550694470839726,
                        "recall": 0.32976084271342565,
                        "fmeasure": 0.19633220761040307
                    }
                },
                "METEOR": 0.24058701276269628,
                "BERTScore": {
                    "Precision": -0.034,
                    "Recall": 0.199,
                    "F1_measure": 0.081
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.19260731320848054,
                    "2_gram": 0.28026104427537213,
                    "3_gram": 0.2357541062754527,
                    "4_gram": 0.18842554247230353
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.37786880621467084,
                        "recall": 0.43398857716764094,
                        "fmeasure": 0.36272134794691185
                    },
                    "rouge_L": {
                        "precision": 0.34045655263700375,
                        "recall": 0.4001286681751763,
                        "fmeasure": 0.3311444649414574
                    }
                },
                "METEOR": 0.3096219151329693,
                "BERTScore": {
                    "Precision": 0.239,
                    "Recall": 0.387,
                    "F1_measure": 0.311
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive studies that aim to collate and analyze all relevant studies on a particular topic. Systematic reviews and meta-analyses provide a synthesized view of the available evidence and help to identify trends",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend the use of a beta-lactam/beta-lactamase inhibitor",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited and mainly comes from small, open-label studies.",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population for the trial, including age, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for CRE infections due to the high risk of treatment failure with monotherapy. The specific combination regimens and duration of therapy depend on the patient's clinical condition, infection site, and susceptibility patterns. Consult",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic selection: Choice of antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10223700977090125,
                    "2_gram": 0.15792098807474866,
                    "3_gram": 0.12055002293853967,
                    "4_gram": 0.09015118504845761
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21188464871984478,
                        "recall": 0.4613991466741049,
                        "fmeasure": 0.2839308296716341
                    },
                    "rouge_L": {
                        "precision": 0.157464388940235,
                        "recall": 0.3556547869530751,
                        "fmeasure": 0.21340618929595107
                    }
                },
                "METEOR": 0.2666020173793365,
                "BERTScore": {
                    "Precision": -0.006,
                    "Recall": 0.226,
                    "F1_measure": 0.108
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.16446104380033236,
                    "2_gram": 0.24770573361328183,
                    "3_gram": 0.20768901306744195,
                    "4_gram": 0.16565171313779856
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3583516660252618,
                        "recall": 0.5346326995508937,
                        "fmeasure": 0.3771630257344543
                    },
                    "rouge_L": {
                        "precision": 0.2964712918660287,
                        "recall": 0.42948799644754804,
                        "fmeasure": 0.3099071183281709
                    }
                },
                "METEOR": 0.318185847193223,
                "BERTScore": {
                    "Precision": 0.268,
                    "Recall": 0.422,
                    "F1_measure": 0.342
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 50,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor combination as",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against some multidrug-resistant bacteria, including Carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a microRNA that plays a role in the regulation of Epstein-Barr virus (EBV) infection and lymphomagenesis. However, there is limited evidence regarding the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients.\n\nSome studies suggest that EBV infection may increase the risk of postoperative infections in liver transplant recipients. For",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including demographics, comorbidities"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting an infectious disease specialist is recommended for individualized treatment decisions.",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in liver transplant recipients.",
                "Developing and validating more accurate and cost-effective preoperative screening tests for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09886448627418355,
                    "2_gram": 0.15560200595017334,
                    "3_gram": 0.1277008100360382,
                    "4_gram": 0.09932803582436353
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.22773642332567015,
                        "recall": 0.49072871755041125,
                        "fmeasure": 0.3055683172445667
                    },
                    "rouge_L": {
                        "precision": 0.17357202056207882,
                        "recall": 0.3817226666794914,
                        "fmeasure": 0.23413035717325853
                    }
                },
                "METEOR": 0.30595984354401345,
                "BERTScore": {
                    "Precision": 0.038,
                    "Recall": 0.273,
                    "F1_measure": 0.154
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.17350031840258193,
                    "2_gram": 0.25520705195732984,
                    "3_gram": 0.22019281502962437,
                    "4_gram": 0.17865334453414364
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36263483383784134,
                        "recall": 0.46501081285583634,
                        "fmeasure": 0.35288184118614485
                    },
                    "rouge_L": {
                        "precision": 0.3071721782812008,
                        "recall": 0.4054196734661816,
                        "fmeasure": 0.3024321097522691
                    }
                },
                "METEOR": 0.32001474336753516,
                "BERTScore": {
                    "Precision": 0.244,
                    "Recall": 0.373,
                    "F1_measure": 0.306
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamase (ESBL)-producing Klebsiella pneumoniae or other 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE), the recommended targeted therapy depends on",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend using these agents as monotherapy, if possible, due to their pot",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB).\n\nSeveral studies have reported the clinical efficacy of eravacycline",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are commonly recommended for patients with bloodstream infections (BSIs) and severe infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is suggested for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting infectious disease specialists is recommended for individualized treatment plans.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10306947074236318,
                    "2_gram": 0.1567801714971418,
                    "3_gram": 0.12075963229741246,
                    "4_gram": 0.09234732569952471
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20487322925008475,
                        "recall": 0.46008210636676017,
                        "fmeasure": 0.2778982165946228
                    },
                    "rouge_L": {
                        "precision": 0.16101301990707848,
                        "recall": 0.3702444274516688,
                        "fmeasure": 0.22015652132255265
                    }
                },
                "METEOR": 0.2596745354260515,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.253,
                    "F1_measure": 0.113
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18271064201551118,
                    "2_gram": 0.25762389740142955,
                    "3_gram": 0.20921391114636445,
                    "4_gram": 0.16453991831212317
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3352723109160193,
                        "recall": 0.4192493481426976,
                        "fmeasure": 0.32543833303663916
                    },
                    "rouge_L": {
                        "precision": 0.29434695337881955,
                        "recall": 0.3748074285682224,
                        "fmeasure": 0.28876294493267957
                    }
                },
                "METEOR": 0.26362473863680524,
                "BERTScore": {
                    "Precision": 0.199,
                    "Recall": 0.371,
                    "F1_measure": 0.283
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few small studies have reported promising results",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including the type of surgery, patient risk factors"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSIs) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the effectiveness and safety of various antibiotic regimens for treating 3GCephRE infections. The evidence is then synthesized and graded based on the quality of the studies, and recommendations for treatment are made accordingly.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10025106972389895,
                    "2_gram": 0.15583266305499896,
                    "3_gram": 0.11886784145993103,
                    "4_gram": 0.08973896867036454
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21061083997207627,
                        "recall": 0.46650118749043157,
                        "fmeasure": 0.28372040694108
                    },
                    "rouge_L": {
                        "precision": 0.15255140902644723,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20769209136973205
                    }
                },
                "METEOR": 0.2684742082392149,
                "BERTScore": {
                    "Precision": -0.007,
                    "Recall": 0.228,
                    "F1_measure": 0.108
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1665663661870372,
                    "2_gram": 0.2542110578349102,
                    "3_gram": 0.22163211850226444,
                    "4_gram": 0.18065293738349086
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3739544477724674,
                        "recall": 0.5342547706015363,
                        "fmeasure": 0.38953091790530214
                    },
                    "rouge_L": {
                        "precision": 0.31152257096089137,
                        "recall": 0.4344010727891958,
                        "fmeasure": 0.32354040048621335
                    }
                },
                "METEOR": 0.304102863636011,
                "BERTScore": {
                    "Precision": 0.29,
                    "Recall": 0.427,
                    "F1_measure": 0.355
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical evidence on the efficacy of eravacycline against CRAB infections",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population based on specific risk factors, such as American Society of"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the efficacy and safety of various antibiotics for treating 3GCephRE infections. The results are then synthesized to provide evidence-based recommendations for clinical practice.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections based on clinical studies and in vitro data.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09965327661841385,
                    "2_gram": 0.15519290220902862,
                    "3_gram": 0.11764599957040625,
                    "4_gram": 0.08866733829992414
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2024513670607011,
                        "recall": 0.4540788272419843,
                        "fmeasure": 0.2737442987691249
                    },
                    "rouge_L": {
                        "precision": 0.15179421244886698,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20698126914611523
                    }
                },
                "METEOR": 0.2607003474896515,
                "BERTScore": {
                    "Precision": -0.03,
                    "Recall": 0.201,
                    "F1_measure": 0.084
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18019534273978538,
                    "2_gram": 0.2681325168103154,
                    "3_gram": 0.23520417827183326,
                    "4_gram": 0.19144596978832432
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.406453658215672,
                        "recall": 0.5466771308499835,
                        "fmeasure": 0.41538931737689494
                    },
                    "rouge_L": {
                        "precision": 0.33431681245999645,
                        "recall": 0.4406122529134194,
                        "fmeasure": 0.3411548699747457
                    }
                },
                "METEOR": 0.3347969254534747,
                "BERTScore": {
                    "Precision": 0.278,
                    "Recall": 0.454,
                    "F1_measure": 0.362
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations for the diagnosis",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few small studies have reported promising results",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting an infectious disease specialist is recommended for individualized treatment decisions.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10126711046021677,
                    "2_gram": 0.15447927880121776,
                    "3_gram": 0.11875277819204588,
                    "4_gram": 0.090809413296556
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21210022430127648,
                        "recall": 0.47160322830675805,
                        "fmeasure": 0.28628484449859404
                    },
                    "rouge_L": {
                        "precision": 0.1571859543006227,
                        "recall": 0.36056786329472285,
                        "fmeasure": 0.2141224552112519
                    }
                },
                "METEOR": 0.26660844905101583,
                "BERTScore": {
                    "Precision": -0.002,
                    "Recall": 0.245,
                    "F1_measure": 0.119
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.20295186401208684,
                    "2_gram": 0.2873491746477991,
                    "3_gram": 0.23917772789734254,
                    "4_gram": 0.1904201527357525
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3940862395749614,
                        "recall": 0.5212901644692283,
                        "fmeasure": 0.3827804670255199
                    },
                    "rouge_L": {
                        "precision": 0.3380576816667042,
                        "recall": 0.4232768163233244,
                        "fmeasure": 0.32249811752658053
                    }
                },
                "METEOR": 0.3175404287664102,
                "BERTScore": {
                    "Precision": 0.311,
                    "Recall": 0.44,
                    "F1_measure": 0.372
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bacteremia or sepsis caused by extended-spectrum \u03b2-lactamase (ESBL)-producing Klebsiella pneumoniae or other 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE), the recommended targeted therapy depends on",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend using these agents as monotherapy, if possible, due to their pot",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB).\n\nSeveral studies have reported the clinical efficacy of eravacycline",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection. The relationship between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients, is not well established.\n\nSome studies suggest that EBV reactivation and infection may increase the risk of postoperative infections, particularly in immunocompromised patients such as liver transplant recipients.",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are commonly recommended for patients with bloodstream infections (BSIs) and severe infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is suggested for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting infectious disease specialists is recommended for individualized treatment plans.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10181061479723914,
                    "2_gram": 0.1557234011308591,
                    "3_gram": 0.12218342311448131,
                    "4_gram": 0.09450602864056609
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.22025784463470013,
                        "recall": 0.4844723502691992,
                        "fmeasure": 0.29676614112292476
                    },
                    "rouge_L": {
                        "precision": 0.17419983309389167,
                        "recall": 0.3911503507966165,
                        "fmeasure": 0.2363290280610971
                    }
                },
                "METEOR": 0.2817771163652928,
                "BERTScore": {
                    "Precision": -0.001,
                    "Recall": 0.261,
                    "F1_measure": 0.127
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18271064201551118,
                    "2_gram": 0.25762389740142955,
                    "3_gram": 0.20921391114636445,
                    "4_gram": 0.16453991831212317
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3352723109160193,
                        "recall": 0.4192493481426976,
                        "fmeasure": 0.32543833303663916
                    },
                    "rouge_L": {
                        "precision": 0.29434695337881955,
                        "recall": 0.3748074285682224,
                        "fmeasure": 0.28876294493267957
                    }
                },
                "METEOR": 0.26362473863680524,
                "BERTScore": {
                    "Precision": 0.199,
                    "Recall": 0.371,
                    "F1_measure": 0.283
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few small studies have reported promising results",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population clearly, including the type of surgery, patient comor"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSIs) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the effectiveness and safety of various antibiotic regimens for treating 3GCephRE infections. The evidence is then synthesized and graded based on the quality of the studies, and recommendations for treatment are made accordingly.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB infections.\n\nDon't say: The current evidence indicates that eravacycline is effective against CRAB infections based on various clinical studies and trials.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10052712217386443,
                    "2_gram": 0.15623943329925954,
                    "3_gram": 0.11921728235449972,
                    "4_gram": 0.08998010684253721
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21121488708775127,
                        "recall": 0.46650118749043157,
                        "fmeasure": 0.2844625219689093
                    },
                    "rouge_L": {
                        "precision": 0.15300444436320348,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20824867764060406
                    }
                },
                "METEOR": 0.26877271433686883,
                "BERTScore": {
                    "Precision": -0.01,
                    "Recall": 0.228,
                    "F1_measure": 0.107
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.1665663661870372,
                    "2_gram": 0.2542110578349102,
                    "3_gram": 0.22163211850226444,
                    "4_gram": 0.18065293738349086
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3739544477724674,
                        "recall": 0.5342547706015363,
                        "fmeasure": 0.38953091790530214
                    },
                    "rouge_L": {
                        "precision": 0.31152257096089137,
                        "recall": 0.4344010727891958,
                        "fmeasure": 0.32354040048621335
                    }
                },
                "METEOR": 0.304102863636011,
                "BERTScore": {
                    "Precision": 0.29,
                    "Recall": 0.427,
                    "F1_measure": 0.355
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical evidence on the efficacy of eravacycline against CRAB infections",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population based on specific risk factors, such as American Society of"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the efficacy and safety of various antibiotics for treating 3GCephRE infections. The results are then synthesized to provide evidence-based recommendations for clinical practice.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections based on clinical studies and in vitro data.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09965327661841385,
                    "2_gram": 0.15519290220902862,
                    "3_gram": 0.11764599957040625,
                    "4_gram": 0.08866733829992414
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2024513670607011,
                        "recall": 0.4540788272419843,
                        "fmeasure": 0.2737442987691249
                    },
                    "rouge_L": {
                        "precision": 0.15179421244886698,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20698126914611523
                    }
                },
                "METEOR": 0.2607003474896515,
                "BERTScore": {
                    "Precision": -0.03,
                    "Recall": 0.201,
                    "F1_measure": 0.084
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18019534273978538,
                    "2_gram": 0.2681325168103154,
                    "3_gram": 0.23520417827183326,
                    "4_gram": 0.19144596978832432
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.406453658215672,
                        "recall": 0.5466771308499835,
                        "fmeasure": 0.41538931737689494
                    },
                    "rouge_L": {
                        "precision": 0.33431681245999645,
                        "recall": 0.4406122529134194,
                        "fmeasure": 0.3411548699747457
                    }
                },
                "METEOR": 0.3347969254534747,
                "BERTScore": {
                    "Precision": 0.278,
                    "Recall": 0.454,
                    "F1_measure": 0.362
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 32,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations for the diagnosis",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few small studies have reported promising results",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or when monotherapy fails. The choice of agents depends on the specific susceptibility pattern and local resistance patterns. Consulting an infectious disease specialist is recommended for individualized treatment decisions.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10126711046021677,
                    "2_gram": 0.15447927880121776,
                    "3_gram": 0.11875277819204588,
                    "4_gram": 0.090809413296556
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.21210022430127648,
                        "recall": 0.47160322830675805,
                        "fmeasure": 0.28628484449859404
                    },
                    "rouge_L": {
                        "precision": 0.1571859543006227,
                        "recall": 0.36056786329472285,
                        "fmeasure": 0.2141224552112519
                    }
                },
                "METEOR": 0.26660844905101583,
                "BERTScore": {
                    "Precision": -0.002,
                    "Recall": 0.245,
                    "F1_measure": 0.119
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.20295186401208684,
                    "2_gram": 0.2873491746477991,
                    "3_gram": 0.23917772789734254,
                    "4_gram": 0.1904201527357525
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3940862395749614,
                        "recall": 0.5212901644692283,
                        "fmeasure": 0.3827804670255199
                    },
                    "rouge_L": {
                        "precision": 0.3380576816667042,
                        "recall": 0.4232768163233244,
                        "fmeasure": 0.32249811752658053
                    }
                },
                "METEOR": 0.3175404287664102,
                "BERTScore": {
                    "Precision": 0.311,
                    "Recall": 0.44,
                    "F1_measure": 0.372
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy, if possible, due to",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including those causing carbapenem-resistant Acinetobacter baumannii (CRAB) infections.\n\nSeveral studies have reported the clinical efficacy of",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nRegarding the association between ESCR-E carrier status and postoperative in",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy may not be sufficient to achieve adequate clinical response. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting the most recent evidence",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Timing of administration: Optimizing the timing of antibi"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10197370896867468,
                    "2_gram": 0.1521043928894392,
                    "3_gram": 0.11722341426106349,
                    "4_gram": 0.08903625853333193
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.19821105239987474,
                        "recall": 0.43525632239463474,
                        "fmeasure": 0.2654278323800066
                    },
                    "rouge_L": {
                        "precision": 0.1542821851997294,
                        "recall": 0.34798278920381637,
                        "fmeasure": 0.20851175863384216
                    }
                },
                "METEOR": 0.2414853704154627,
                "BERTScore": {
                    "Precision": -0.019,
                    "Recall": 0.234,
                    "F1_measure": 0.105
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.17939036073056017,
                    "2_gram": 0.25505605302622786,
                    "3_gram": 0.21263303927877222,
                    "4_gram": 0.16850331540923028
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.33841680375280786,
                        "recall": 0.4549636338569833,
                        "fmeasure": 0.3339306289180976
                    },
                    "rouge_L": {
                        "precision": 0.30046195038699564,
                        "recall": 0.4158127195735134,
                        "fmeasure": 0.3011798875959277
                    }
                },
                "METEOR": 0.28090745100899267,
                "BERTScore": {
                    "Precision": 0.195,
                    "Recall": 0.385,
                    "F1_measure": 0.287
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive studies that aim to collate and analyze all relevant studies on a particular topic. Systematic reviews and meta-analyses provide a summary of the available evidence and help to identify trends and inconsist",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical evidence on the efficacy of eravacycline against CRAB infections",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population based on specific risk factors, such as American Society of"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the effectiveness and safety of various antibiotics and treatment strategies. The evidence is then graded based on its quality and certainty, and recommendations for treatment are made based on this evidence.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy may not be sufficient. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting the most recent evidence-based guidelines and infect",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09992946933244021,
                    "2_gram": 0.1546830413761055,
                    "3_gram": 0.1160794843701617,
                    "4_gram": 0.08731422768603676
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20134988863073564,
                        "recall": 0.4489767864256578,
                        "fmeasure": 0.2712592134095636
                    },
                    "rouge_L": {
                        "precision": 0.1518540443124244,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20675412815843847
                    }
                },
                "METEOR": 0.257188816533236,
                "BERTScore": {
                    "Precision": -0.03,
                    "Recall": 0.2,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18984896735384652,
                    "2_gram": 0.2743799648931185,
                    "3_gram": 0.23251527211553186,
                    "4_gram": 0.18501762616672804
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.37408059776480834,
                        "recall": 0.5263922052855547,
                        "fmeasure": 0.3683323026180169
                    },
                    "rouge_L": {
                        "precision": 0.3205772923818037,
                        "recall": 0.43366986243065625,
                        "fmeasure": 0.3114945372088229
                    }
                },
                "METEOR": 0.29620019246225987,
                "BERTScore": {
                    "Precision": 0.3,
                    "Recall": 0.435,
                    "F1_measure": 0.364
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor combination as",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, including those commonly implicated in complex intra-abdominal infections (cIAIs) and bloodstream infections (BSIs) caused by Carbapenem-resistant Acinet",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically a carbapenem antibiotic.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the efficacy and safety of various antibiotics for treating 3GCephRE infections. The results are then synthesized to provide evidence-based recommendations for clinical practice.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotic combinations based on individual patient's clinical condition and susceptibility testing results.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections based on clinical studies and in vitro data.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors and type of surgery.\n2. Antibiotic regimen: Choice of effective antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09794792363715529,
                    "2_gram": 0.15233605714624426,
                    "3_gram": 0.11344645725351632,
                    "4_gram": 0.08544352349393372
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18745736466946283,
                        "recall": 0.42831393191187156,
                        "fmeasure": 0.2545362966210139
                    },
                    "rouge_L": {
                        "precision": 0.13413602682881512,
                        "recall": 0.3193078810409518,
                        "fmeasure": 0.18428490924467364
                    }
                },
                "METEOR": 0.2404860728872217,
                "BERTScore": {
                    "Precision": -0.043,
                    "Recall": 0.184,
                    "F1_measure": 0.069
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18066426148420997,
                    "2_gram": 0.2649223684295633,
                    "3_gram": 0.2322292763078217,
                    "4_gram": 0.18771179061439394
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3918498409802758,
                        "recall": 0.4931057022785549,
                        "fmeasure": 0.3924388038381462
                    },
                    "rouge_L": {
                        "precision": 0.3241265015178059,
                        "recall": 0.4048979671991337,
                        "fmeasure": 0.3253192023743723
                    }
                },
                "METEOR": 0.34589333798462935,
                "BERTScore": {
                    "Precision": 0.257,
                    "Recall": 0.405,
                    "F1_measure": 0.329
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 4,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations for the diagnosis",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor combination as",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few small studies have reported promising results",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10065344949605252,
                    "2_gram": 0.15418555360434485,
                    "3_gram": 0.11974107634012585,
                    "4_gram": 0.0927487094577849
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2147404168250499,
                        "recall": 0.4768942335977634,
                        "fmeasure": 0.28975526150284564
                    },
                    "rouge_L": {
                        "precision": 0.15688646343509413,
                        "recall": 0.36056786329472285,
                        "fmeasure": 0.2138295150686877
                    }
                },
                "METEOR": 0.2731072897066053,
                "BERTScore": {
                    "Precision": 0.003,
                    "Recall": 0.25,
                    "F1_measure": 0.125
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.21329482936700317,
                    "2_gram": 0.30467445463997395,
                    "3_gram": 0.2594886989775444,
                    "4_gram": 0.21026130808944354
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.41825651374523554,
                        "recall": 0.5054171485962123,
                        "fmeasure": 0.3984340402827798
                    },
                    "rouge_L": {
                        "precision": 0.3647532083622309,
                        "recall": 0.4179858110323192,
                        "fmeasure": 0.34283313325330134
                    }
                },
                "METEOR": 0.3175641709800083,
                "BERTScore": {
                    "Precision": 0.346,
                    "Recall": 0.444,
                    "F1_measure": 0.392
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 10
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacteriaceae (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCephRs) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Professional organizations, such as the Infectious Diseases Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Centers for Disease Control and Pre",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy, if possible, due to",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown promise in the treatment of complex infections caused by multidrug-resistant bacteria, including those causing carbapenem-resistant Acinetobacter baumannii (CRAB) infections.\n\nSeveral studies have reported the clinical efficacy of",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection or reactivation. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and gastric cancer.\n\nRegarding the association between ESCR-E carrier status and postoperative in",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific surgical procedures, patient risk factors, and"
            ],
            "additional prompt / finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual clinical studies, which are regularly updated in databases such as Cochrane Library and PubMed. Recommendations are based on the quality of evidence and the balance between benefits and harms.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not explicitly stated in current guidelines. However, the use of combination therapy is generally considered for severe infections or in cases where monotherapy may not be sufficient to achieve adequate clinical response. The choice of agents for combination therapy depends on the specific susceptibility pattern and local resistance patterns. Consulting the most recent evidence",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Timing of administration: Optimizing the timing of antibi"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10197370896867468,
                    "2_gram": 0.1521043928894392,
                    "3_gram": 0.11722341426106349,
                    "4_gram": 0.08903625853333193
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.19821105239987474,
                        "recall": 0.43525632239463474,
                        "fmeasure": 0.2654278323800066
                    },
                    "rouge_L": {
                        "precision": 0.1542821851997294,
                        "recall": 0.34798278920381637,
                        "fmeasure": 0.20851175863384216
                    }
                },
                "METEOR": 0.2414853704154627,
                "BERTScore": {
                    "Precision": -0.019,
                    "Recall": 0.234,
                    "F1_measure": 0.105
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.17939036073056017,
                    "2_gram": 0.25505605302622786,
                    "3_gram": 0.21263303927877222,
                    "4_gram": 0.16850331540923028
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.33841680375280786,
                        "recall": 0.4549636338569833,
                        "fmeasure": 0.3339306289180976
                    },
                    "rouge_L": {
                        "precision": 0.30046195038699564,
                        "recall": 0.4158127195735134,
                        "fmeasure": 0.3011798875959277
                    }
                },
                "METEOR": 0.28090745100899267,
                "BERTScore": {
                    "Precision": 0.195,
                    "Recall": 0.385,
                    "F1_measure": 0.287
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 50
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive studies that aim to collate and analyze all relevant studies on a particular topic. Systematic reviews and meta-analyses provide a summary of the available evidence and help to identify trends and inconsist",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor or a",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB). However, the clinical evidence on the efficacy of eravacycline against CRAB infections",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient Population: Define the patient population based on specific risk factors, such as American Society of"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective diagnostic tests for MDR-GNB preoperative screening.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09992946933244021,
                    "2_gram": 0.1546830413761055,
                    "3_gram": 0.1160794843701617,
                    "4_gram": 0.08731422768603676
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.20134988863073564,
                        "recall": 0.4489767864256578,
                        "fmeasure": 0.2712592134095636
                    },
                    "rouge_L": {
                        "precision": 0.1518540443124244,
                        "recall": 0.35036378166206983,
                        "fmeasure": 0.20675412815843847
                    }
                },
                "METEOR": 0.257188816533236,
                "BERTScore": {
                    "Precision": -0.03,
                    "Recall": 0.2,
                    "F1_measure": 0.083
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.20935382989028942,
                    "2_gram": 0.30525924996161136,
                    "3_gram": 0.2593008638626234,
                    "4_gram": 0.20895213339317206
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.41825651374523554,
                        "recall": 0.5054171485962123,
                        "fmeasure": 0.3984340402827798
                    },
                    "rouge_L": {
                        "precision": 0.3647532083622309,
                        "recall": 0.4179858110323192,
                        "fmeasure": 0.34283313325330134
                    }
                },
                "METEOR": 0.3175641709800083,
                "BERTScore": {
                    "Precision": 0.344,
                    "Recall": 0.44,
                    "F1_measure": 0.389
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 100
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized and presented in various ways, depending on the source of the information. Here are some common ways:\n\n1. Systematic Reviews and Meta-analyses: These are comprehensive analyses of all available evidence on a particular topic. Systematic reviews often include meta-analyses, which use statistical methods to combine the results of multiple studies. For example, the Cochr",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor combination as",
                "Eravacycline is a new, lipidated, fluorinated tetracycline antibiotic that has shown activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, including those commonly implicated in complex intra-abdominal infections (cIAIs) and bloodstream infections (BSIs) caused by Carbapenem-resistant Acinet",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "The recommended targeted therapy for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE) is typically a carbapenem antibiotic.",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized through systematic reviews and meta-analyses of clinical studies. These studies evaluate the efficacy and safety of various antibiotics for treating 3GCephRE infections. The results are then synthesized to provide evidence-based recommendations for clinical practice.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotic combinations based on individual patient's clinical condition and susceptibility testing results.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections based on clinical studies and in vitro data.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors and type of surgery.\n2. Antibiotic regimen: Choice of effective antibiotics with"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.09794792363715529,
                    "2_gram": 0.15233605714624426,
                    "3_gram": 0.11344645725351632,
                    "4_gram": 0.08544352349393372
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18745736466946283,
                        "recall": 0.42831393191187156,
                        "fmeasure": 0.2545362966210139
                    },
                    "rouge_L": {
                        "precision": 0.13413602682881512,
                        "recall": 0.3193078810409518,
                        "fmeasure": 0.18428490924467364
                    }
                },
                "METEOR": 0.2404860728872217,
                "BERTScore": {
                    "Precision": -0.043,
                    "Recall": 0.184,
                    "F1_measure": 0.069
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.18066426148420997,
                    "2_gram": 0.2649223684295633,
                    "3_gram": 0.2322292763078217,
                    "4_gram": 0.18771179061439394
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.3918498409802758,
                        "recall": 0.4931057022785549,
                        "fmeasure": 0.3924388038381462
                    },
                    "rouge_L": {
                        "precision": 0.3241265015178059,
                        "recall": 0.4048979671991337,
                        "fmeasure": 0.3253192023743723
                    }
                },
                "METEOR": 0.34589333798462935,
                "BERTScore": {
                    "Precision": 0.257,
                    "Recall": 0.405,
                    "F1_measure": 0.329
                }
            }
        }
    },
    {
        "parameters": {
            "llm": "TheBloke/Mistral-7B-Instruct-v0.2-GPTQ",  
            "rank": 100,
            "lora_alpha": 64,
            "lora_dropout": 0.05,
            "learning_rate": 0.0002,
            "batch_size": 10,
            "num_epochs": 200
        },
        "queries": [
            "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?",
            "How is the evidence on treatment of infections caused by 3GCephRE organized?",
            "What is the recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?",
            "What is the current evidence on the clinical efficacy of eravacycline against CRAB infections?",
            "What is the association between ESCR-E carrier status and postoperative infections in patients undergoing surgery, including liver transplant recipients?",
            "What is a suggested area of future research in the context of preoperative screening for MDR-GNB?",
            "What should be considered when designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP)?"
        ],
        "reference answers": [
            "A carbapenem (imipenem or meropenem) as targeted therapy",
            "The evidence on treatment of infections caused by 3GCephRE is organized by clinical syndrome, including bloodstream infections (BSI), urinary tract infections (UTI), pneumonia, and intra-abdominal infection (IAI).",
            "We do not recommend combination therapy for patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol (strong recommendation against use, low certainty of evidence).",
            "There are no available data on the clinical efficacy of eravacycline against CRAB infections, despite its potential in vitro activity against these organisms.",
            "ESCR-E carrier status is an independent predictor of postoperative infections, including surgical site infections (SSIs) and bloodstream infections, with higher odds of SSIs caused by ESCR-E, and is associated with increased risk of postoperative infections in liver transplant recipients.",
            "Studies analyzing the optimal timing for preoperative screening and evaluating the benefits of additional screening before surgery in case of recent antibiotic treatment.",
            "Clinical trials of targeted PAP should be designed considering rectal culture results."
        ],
        "predicted answers": {
            "no additional prompt / no finetuning": [
                "For patients with bacteremia (BSI, or bloodstream infection) and severe infection caused by extended-spectrum \u03b2-lactamases producing Klebsiella pneumoniae or other Enterobacterales (3GCephalosporin-resistant, 3GCephalosporin-res",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCs) is organized through various sources, including peer-reviewed scientific journals, clinical guidelines, and meta-analyses. Here are some ways the evidence is typically organized:\n\n1. Peer-reviewed scientific journals: Research studies on the treatment of infections caused by 3GCs are published in scientific journals. These studies can be categorized based on their study",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend the use of these agents as monotherapy based on their in vitro",
                "Eravacycline is a new, fluorinated, narrow-spectrum tetracycline antibiotic that has shown activity against a broad range of Gram-negative bacteria, including those that are resistant to other tetracyclines and fluoroquinolones. It has been studied for the treatment of complex infections caused by multidrug-resistant (MDR) and extensively",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-EBV-encoded small RNAs) is a biomarker associated with EBV infection, which is a common virus that can cause various diseases, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a type of cancer that can develop in people who have undergone organ transplantation.\n\nThe association between ESCR-E carrier status and postoperative infections in patients undergoing surgery,",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB,",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) involves careful consideration of several key factors to ensure valid and reliable results. Here are some important aspects to consider:\n\n1. Patient Population: Defining the patient population is crucial. This includes considering the type of"
            ],
            "additional prompt / no finetuning": [
                "Carbapenems and polymyxins are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection due to 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into evidence-based guidelines, which provide recommendations based on a systematic review of available scientific evidence. These guidelines aim to help healthcare professionals make informed decisions about the most effective and safe treatment options for patients with 3GCephRE infections.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is not universally agreed upon and depends on individual patient factors. Consult current guidelines or a medical expert for specific recommendations.",
                "The current evidence shows that eravacycline is effective against CRAB (carbapenem-resistant Acinetobacter baumannii) infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on type of surgery, risk factors, and microbial spectrum.\n2. Antibiotic selection: Choice of"
            ],
            "no additional prompt / finetuning": [
                "For patients with bloodstream infections (BSIs) and severe infections caused by extended-spectrum cephalosporin-resistant Enterobacterales (3GCephalosporin-RE), the recommended targeted therapy depends on the specific organism and its susceptibility patterns. Here are some general guidelines:",
                "The evidence on the treatment of infections caused by third-generation cephalosporins (3GCeph) is organized in various ways, depending on the source of the information. Here are some common ways:\n\n1. Guidelines: Evidence-based clinical practice guidelines, such as those developed by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), provide recommendations for the diagnosis",
                "In patients with complicated infections caused by Carbapenem-resistant Enterobacterales (CRE) that are susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend using a beta-lactam/beta-lactamase inhibitor combination as",
                "Eravacycline is a new, lipid-modified tetracycline antibiotic that has shown activity against Carbapenem-resistant Acinetobacter baumannii (CRAB) in vitro. However, the clinical evidence on the efficacy of eravacycline against CRAB infections is still limited.\n\nA few small studies have reported promising results",
                "ESCR-E (Epstein-Barr virus-encoded small RNAs-E) is a biomarker associated with Epstein-Barr virus (EBV) infection. EBV is a human herpesvirus that can cause various diseases, including infectious mononucleosis and malignancies such as Burkitt lymphoma and gastric cancer.\n\nCarrier status for EBV refers to the presence of the virus in an individual's body without causing symptoms. The association between EBV carrier",
                "Preoperative screening for multidrug-resistant Gram-negative bacteria (MDR-GNB) is an important area of research to reduce the risk of post-surgical infections and improve patient outcomes. Here are some suggested areas of future research in this context:\n\n1. Development of rapid and accurate diagnostic methods: Current methods for detecting MDR-GNB are",
                "Designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP) requires careful consideration of several factors to ensure valid and reliable results. Here are some key aspects to consider:\n\n1. Patient population: Define the patient population based on specific risk factors, such as American Society of An"
            ],
            "additional prompt / finetuning": [
                "Carbapenems, such as meropenem or imipenem, are the recommended targeted therapies for patients with bloodstream infections (BSI) and severe infection caused by 3rd generation cephalosporin-resistant Enterobacterales (3GCephRE).",
                "The evidence on treatment of infections caused by 3GCephalosporin-resistant Enterobacterales (3GCephRE) is organized into systematic reviews and meta-analyses, as well as individual studies, which are assessed for quality and relevance to inform recommendations.",
                "The recommendation for combination therapy in patients with CRE infections susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol is to consider using these antibiotics in combination based on individual patient's clinical condition and infection severity.",
                "The current evidence shows that eravacycline is effective against CRAB infections.",
                "ESCR-E carrier status is associated with an increased risk of postoperative infections, including in patients undergoing surgery and liver transplant recipients.",
                "Developing more accurate and cost-effective methods for preoperative screening for MDR-GNB.",
                "When designing clinical trials of targeted perioperative antibiotic prophylaxis (PAP), the following should be considered:\n\n1. Patient population: Selection of appropriate patient population based on risk factors for surgical site infections.\n2. Antibiotic regimen: Choice of effective antibiot"
            ]
        },
        "metrics": {
            "no additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.09872057369288065,
                    "2_gram": 0.1497020060704794,
                    "3_gram": 0.11507925097628226,
                    "4_gram": 0.08705521638739029
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.18929977255448954,
                        "recall": 0.428360722160904,
                        "fmeasure": 0.25851908102258
                    },
                    "rouge_L": {
                        "precision": 0.14602598659202431,
                        "recall": 0.3336099669041648,
                        "fmeasure": 0.20016017937784594
                    }
                },
                "METEOR": 0.24009821826233188,
                "BERTScore": {
                    "Precision": -0.022,
                    "Recall": 0.219,
                    "F1_measure": 0.097
                }
            },
            "additional prompt / no finetuning": {
                "BLEU": {
                    "1_gram": 0.18816024536375914,
                    "2_gram": 0.2669254558197965,
                    "3_gram": 0.22676809981951693,
                    "4_gram": 0.18213831212464093
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.36690365576164974,
                        "recall": 0.44438162327497277,
                        "fmeasure": 0.35668787167534033
                    },
                    "rouge_L": {
                        "precision": 0.3253487194698713,
                        "recall": 0.4052307089915028,
                        "fmeasure": 0.3207736271896673
                    }
                },
                "METEOR": 0.29836528723470174,
                "BERTScore": {
                    "Precision": 0.233,
                    "Recall": 0.388,
                    "F1_measure": 0.308
                }
            },
            "no additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.10065344949605252,
                    "2_gram": 0.15418555360434485,
                    "3_gram": 0.11974107634012585,
                    "4_gram": 0.0927487094577849
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.2147404168250499,
                        "recall": 0.4768942335977634,
                        "fmeasure": 0.28975526150284564
                    },
                    "rouge_L": {
                        "precision": 0.15688646343509413,
                        "recall": 0.36056786329472285,
                        "fmeasure": 0.2138295150686877
                    }
                },
                "METEOR": 0.2731072897066053,
                "BERTScore": {
                    "Precision": 0.003,
                    "Recall": 0.25,
                    "F1_measure": 0.125
                }
            },
            "additional prompt / finetuning": {
                "BLEU": {
                    "1_gram": 0.21329482936700317,
                    "2_gram": 0.30467445463997395,
                    "3_gram": 0.2594886989775444,
                    "4_gram": 0.21026130808944354
                },
                "ROUGE": {
                    "rouge_1": {
                        "precision": 0.41825651374523554,
                        "recall": 0.5054171485962123,
                        "fmeasure": 0.3984340402827798
                    },
                    "rouge_L": {
                        "precision": 0.3647532083622309,
                        "recall": 0.4179858110323192,
                        "fmeasure": 0.34283313325330134
                    }
                },
                "METEOR": 0.3175641709800083,
                "BERTScore": {
                    "Precision": 0.346,
                    "Recall": 0.444,
                    "F1_measure": 0.392
                }
            }
        }
    }
]